FDA probes deaths of two patients on Lilly schizophrenia drug

By Ransdell Pierson (Reuters) – The U.S. Food and Drug Administration is investigating the cases of two individuals who died after injections with Eli Lilly and Co.’s long-acting treatment for schizophrenia, Zyprexa Relprevv. Both patients died three to four days after receiving “an appropriate dose” of the medicine, and both had very high levels of the drug in their bloodstreams, the FDA said in a bulletin released on its website on Tuesday. …